Molnar P, Demeny M, Varkonyi B, Polgar Z, Por A, Kovacs I
Front Pharmacol. 2025; 16:1519066.
PMID: 40046735
PMC: 11879949.
DOI: 10.3389/fphar.2025.1519066.
Gaur P, Bain F, Meah R, Spies M
bioRxiv. 2025; .
PMID: 39829912
PMC: 11741300.
DOI: 10.1101/2025.01.06.631587.
Drew Y, Zenke F, Curtin N
Nat Rev Drug Discov. 2024; 24(1):19-39.
PMID: 39533099
DOI: 10.1038/s41573-024-01060-w.
Bondar D, Karpichev Y
Biomolecules. 2024; 14(10).
PMID: 39456202
PMC: 11506039.
DOI: 10.3390/biom14101269.
Ho W, Marinova M, Listijono D, Bertoldo M, Richani D, Kim L
EMBO Mol Med. 2024; 16(10):2583-2618.
PMID: 39169162
PMC: 11473878.
DOI: 10.1038/s44321-024-00119-w.
Dual-target EZH2 inhibitor: latest advances in medicinal chemistry.
Wei L, Mei D, Hu S, Du S
Future Med Chem. 2024; 16(15):1561-1582.
PMID: 39082677
PMC: 11370917.
DOI: 10.1080/17568919.2024.2380243.
Revisiting 'Hallmarks of Cancer' In Sarcomas.
Honoki K, Tsujiuchi T, Kishi S, Kuniyasu H
J Cancer. 2024; 15(7):1786-1804.
PMID: 38434982
PMC: 10905407.
DOI: 10.7150/jca.92844.
NAD+ associated genes as potential biomarkers for predicting the prognosis of gastric cancer.
Sun X, Wen H, Li F, Bukhari I, Ren F, Xue X
Oncol Res. 2024; 32(2):283-296.
PMID: 38186577
PMC: 10765132.
DOI: 10.32604/or.2023.044618.
Effects of poly (ADP-ribose) polymerase inhibitor treatment on the repair process of ischemic acute kidney injury.
Jeon J, Lee K, Jang H, Yang K, Lee C, Ahn H
Sci Rep. 2024; 14(1):159.
PMID: 38167603
PMC: 10761972.
DOI: 10.1038/s41598-023-50630-2.
Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.
Zhang Y, Liang L, Li Z, Huang Y, Jiang M, Zou B
Front Oncol. 2023; 13:1295579.
PMID: 38111536
PMC: 10726039.
DOI: 10.3389/fonc.2023.1295579.
Evolution of the Development of PARP Inhibitors.
Plummer R
Cancer Treat Res. 2023; 186:1-11.
PMID: 37978127
DOI: 10.1007/978-3-031-30065-3_1.
A new wave of innovations within the DNA damage response.
Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y
Signal Transduct Target Ther. 2023; 8(1):338.
PMID: 37679326
PMC: 10485079.
DOI: 10.1038/s41392-023-01548-8.
PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages.
Santinelli-Pestana D, Aikawa E, Singh S, Aikawa M
Pathogens. 2023; 12(7).
PMID: 37513811
PMC: 10386340.
DOI: 10.3390/pathogens12070964.
Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisation.
Wong W, OBrien-Gortner S, Anderson R, Wilson W, Hay M, Dickson B
RSC Med Chem. 2023; 14(7):1309-1330.
PMID: 37484567
PMC: 10357951.
DOI: 10.1039/d3md00117b.
Multifaceted Role of PARP1 in Maintaining Genome Stability Through Its Binding to Alternative DNA Structures.
Laspata N, Muoio D, Fouquerel E
J Mol Biol. 2023; 436(1):168207.
PMID: 37481154
PMC: 11552663.
DOI: 10.1016/j.jmb.2023.168207.
A New Opportunity for "Old" Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism.
Iglesias P, Seoane M, Golan-Cancela I, Fraga M, Arce V, Costoya J
Int J Mol Sci. 2023; 24(10).
PMID: 37240195
PMC: 10219095.
DOI: 10.3390/ijms24108849.
Clinical Implication of DNA Damage Response Genes in Advanced Gastric Cancer Stage IV and Recurrent Gastric Cancer Patients After Gastrectomy Treated Palliative Chemotherapy.
Kim J, Park S, Kim H, Hwang I
J Cancer. 2023; 14(7):1216-1222.
PMID: 37215456
PMC: 10197943.
DOI: 10.7150/jca.81632.
PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality.
Yakovlev V, Sullivan S, Fields E, Temkin S
Front Oncol. 2023; 13:1124147.
PMID: 36910637
PMC: 9992988.
DOI: 10.3389/fonc.2023.1124147.
Beyond Pellagra-Research Models and Strategies Addressing the Enduring Clinical Relevance of NAD Deficiency in Aging and Disease.
Feuz M, Meyer-Ficca M, Meyer R
Cells. 2023; 12(3).
PMID: 36766842
PMC: 9913999.
DOI: 10.3390/cells12030500.
Roles of NAD in Acute and Chronic Kidney Diseases.
Morevati M, Fang E, Mace M, Kanbay M, Gravesen E, Nordholm A
Int J Mol Sci. 2023; 24(1).
PMID: 36613582
PMC: 9820289.
DOI: 10.3390/ijms24010137.